Carbamazepine Treatment for Cocaine Dependence - 5

This study has been completed.

First Received on September 20, 1999. Last Updated on June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000191

Purpose

The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Carbamazepine	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Carbamazepine Treatment for Cocaine Dependence

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Carbamazepine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	21 Years to 51 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000191

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

James Cornish, M.D.

University of Pennsylvania

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000191 History of Changes
Other Study ID Numbers:	NIDA-00144-5, K20-00144-5
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Carbamazepine
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs

Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs

ClinicalTrials.gov processed this record on February 09, 2012